1/3 Does chronic stress impact disease activity in #MultipleSclerosis?
Our new paper published in Multiple Sclerosis and Related Disorders tackles this critical question by analyzing real-world data during a period of sustained nationwide stress. ๐งต๐
https://t.co/hJriCi8ybb
Honored to present two of my research projects on demyelinating disorders at the Israeli Neuroimmunology Summit, exploring the mechanisms behind NMOSD, MOGAD, and MS.
Excited to be back tomorrow for my final presentation!
@RechtmanAriel presented two groundbreaking projects on demyelinating disorders, shedding new light on the mechanisms driving NMOSD, MOGAD, and MS at the Israeli Neuroimmunology Summit.
#Neuroimmunology#MS#MOGAD#NMOSD
We invite you to read our new publication in Clinical Neurology & Neurosurgery: MOGAD can cause myelitis with completely normal MRI. Our case series + literature review highlight the need for MOG-IgG testing in patients with clinical myelitis despite normal scans.
https://t.co/cx0kQI0v4k
@AVDlaboratory@RechtmanAriel
๐จ New paper from our lab!
sCD83 is reduced in NMOSD and in relapsing MOGAD- correlates with brain volume loss and relapse risk.
๐ A promising biomarker in demyelinating diseases.
Read in Frontiers in Immunology:
๐ https://t.co/ql8Oc772nW
#CD83#Neuroimmunology
Weโre pleased to share that today, on National Stress Awareness Day, our new paper is out: Subclinical imaging activity in multiple sclerosis patients during war-related psychological stress.
Read more here:
https://t.co/XLebgbZK7a
#StressAwareness#MS @TheNewANA1
I'm excited to share a tweet from @neurology_live featuring our article, which evaluates the real-world applicability of the new #MOGAD diagnosis criteria in a live cohort.
A recent real-world study assessing the applicability of the 2023 international #MOGAD panel criteria showed a strong concordance between the new criteria and treating physiciansโ diagnoses. @Hadassah@AVDlaboratory@HebrewU ๐ ๐ง
https://t.co/9UOA3khh7E